Published in Oncol Lett on March 01, 2016
Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell (2010) 14.18
Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin (2010) 5.53
Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res (2005) 5.17
Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res (2002) 4.99
PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol (2009) 4.83
Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med (2010) 3.54
PTEN function: how normal cells control it and tumour cells lose it. Biochem J (2004) 3.06
Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant (2010) 2.50
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A (2009) 2.47
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol (2011) 2.43
Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol (2013) 2.11
The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat Rev Neurosci (2011) 1.66
Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells (2009) 1.40
Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells (2008) 1.38
Advances in mesenchymal stem cell-mediated gene therapy for cancer. Stem Cell Res Ther (2010) 1.29
Potential implications of mesenchymal stem cells in cancer therapy. Cancer Lett (2011) 1.19
Stem cells as vectors for antitumour therapy. Thorax (2010) 1.14
Mesenchymal stem cells: an emerging tool for cancer targeting and therapy. Curr Stem Cell Res Ther (2008) 1.12
Gene therapy for cystic fibrosis lung disease: current status and future perspectives. Curr Opin Mol Ther (2006) 1.04
Therapeutic efficacy and fate of bimodal engineered stem cells in malignant brain tumors. Stem Cells (2013) 1.03
TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells. Cancer Gene Ther (2012) 1.00
Malignant gliomas: diagnosis and treatment. Dis Mon (2011) 0.96
Dynamic assessment of cell viability, proliferation and migration using real time cell analyzer system (RTCA). Cytotechnology (2014) 0.96
Single-cell mRNA transfection studies: delivery, kinetics and statistics by numbers. Nanomedicine (2013) 0.94
Image-guided, tumor stroma-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene delivery. Mol Ther (2011) 0.93
PTEN mutation: many birds with one stone in tumorigenesis. Anticancer Res (2009) 0.93
In vitro effect of adenovirus-mediated human Gamma Interferon gene transfer into human mesenchymal stem cells for chronic myelogenous leukemia. Hematol Oncol (2006) 0.90
Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation. Methods Mol Biol (2010) 0.90
MSC(TRAIL)-mediated HepG2 cell death in direct and indirect co-cultures. Anticancer Res (2011) 0.89
Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor. Biochim Biophys Acta (2014) 0.88
PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. Adv Biol Regul (2014) 0.87
Mesenchymal stem cell-mediated cancer therapy: A dual-targeted strategy of personalized medicine. World J Stem Cells (2011) 0.86
Experimental therapy for lung cancer: umbilical cord-derived mesenchymal stem cell-mediated interleukin-24 delivery. Curr Cancer Drug Targets (2013) 0.85
TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells. Anticancer Res (2014) 0.84
Mesenchymal stem cells as cellular vehicles for prodrug gene therapy against tumors. Biochimie (2014) 0.84
Cancer cell-oriented migration of mesenchymal stem cells engineered with an anticancer gene (PTEN): an imaging demonstration. Onco Targets Ther (2014) 0.82
Cell fate conversion by mRNA. Stem Cell Res Ther (2011) 0.82
Stem cell-mediated gene therapies for malignant gliomas: a promising targeted therapeutic approach? Discov Med (2011) 0.82
Multipotent mesenchymal stromal cells: clinical applications and cancer modeling. Adv Exp Med Biol (2012) 0.81
Reprogramming human umbilical cord mesenchymal stromal cells to islet-like cells with the use of in vitro-synthesized pancreatic-duodenal homebox 1 messenger RNA. Cytotherapy (2014) 0.80
PDX-1 mRNA-induced reprogramming of mouse pancreas-derived mesenchymal stem cells into insulin-producing cells in vitro. Clin Exp Med (2014) 0.77
TALEN-induced disruption of Nanog expression results in reduced proliferation, invasiveness and migration, increased chemosensitivity and reversal of EMT in HepG2 cells. Oncol Rep (2015) 0.80
Forced expression of Nanog with mRNA synthesized in vitro to evaluate the malignancy of HeLa cells through acquiring cancer stem cell phenotypes. Oncol Rep (2016) 0.76
NaHCO3 enhances the antitumor activities of cytokine-induced killer cells against hepatocellular carcinoma HepG2 cells. Oncol Lett (2016) 0.75
TALENs-mediated homozygous CCR5Δ32 mutations endow CD4+ U87 cells with resistance against HIV‑1 infection. Mol Med Rep (2017) 0.75